• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Dis . Persisting Salivary IgG against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys

tetano

Editor, Senior Moderator
J Infect Dis


. 2021 May 12;jiab256.
doi: 10.1093/infdis/jiab256. Online ahead of print.
Persisting Salivary IgG against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys


Hassan Alkharaan[SUP] 1 [/SUP], Shaghayegh Bayati[SUP] 2 [/SUP], Cecilia Hellstr?m[SUP] 2 [/SUP], Soo Aleman[SUP] 3 4 [/SUP], Annika Olsson[SUP] 3 [/SUP], Karin Lindahl[SUP] 3 4 [/SUP], Gordana Bogdanovic[SUP] 5 [/SUP], Katie Healy[SUP] 1 [/SUP], Georgios Tsilingaridis[SUP] 1 [/SUP], Patricia De Palma[SUP] 1 [/SUP], Sophia Hober[SUP] 6 [/SUP], Anna M?nberg[SUP] 2 [/SUP], Peter Nilsson[SUP] 2 [/SUP], Elisa Pin[SUP] 2 [/SUP], Margaret S?llberg Chen[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Declining humoral immunity in COVID-19 patients and the possibility of reinfection have raised concern. Mucosal immunity, particularly salivary antibodies, may be short-lived although long-term studies are lacking.
Methods: Using a multiplex bead-based array platform, we investigated antibodies specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins in 256 saliva samples from convalescent patients 1-9 months after symptomatic COVID-19 (n=74, Cohort 1), undiagnosed individuals with self-reported questionnaires (n=147, Cohort 2), and individuals sampled pre-pandemic time (n= 35, Cohort 3).
Results: Salivary IgG antibody responses in Cohort 1 (mainly mild COVID-19) were detectable up to nine months post-recovery, with high correlations between spike and nucleocapsid specificity. At nine months, IgG remained in both blood and saliva in majority of patients. Salivary IgA was rarely detected at this timepoint. In Cohort 2, salivary IgG and IgA responses were significantly associated with a recent history of COVID-19 like symptoms. Salivary IgG also tolerated temperature and detergent pre-treatments.
Conclusions: Unlike SARS-CoV-2 salivary IgA that appeared short-lived, the specific IgG in saliva appeared stable even after mild COVID-19 as noted for blood serology. This non-invasive saliva-based SARS-CoV-2 antibody test with home self-collection may therefore serve as a complementary alternative to conventional blood serology.

Keywords: COVID-19; antibody; convalescence; immunoassay; saliva; serology.
 
Back
Top Bottom